Kohei Shitara, Director of the Department of Gastrointestinal Oncology at National Cancer Center Hospital East, shared a post on X:
“Pleased to share the DESTINY-Gastric05 phase III protocol: 1L T-DXd+Cape+pembro in HER2+ gastric/GEJ cancer
Recruitment ongoing. Future interpretation may benefit from thoughtful cross-trial context vs zanidatamab-based strategies.”
Title: DESTINY-Gastric05 phase III trial of first-line trastuzumab deruxtecan, chemotherapy, and pembrolizumab in HER2-positive gastric or gastroesophageal junction cancer
Authors: Y.Y. Janjigian, E. Smyth, L. Shen, J. Lee, P.M. Hoff, S. Lonardi, D. Barrios, K. Kobayashi, Y. Okuda, T. Kamio, K. Shitara
